retatrutide triple agonist obesity trial 🚨 Today, retatrutide, the GIP/GLP-1/glucagon agonist, just delivered TRIUMPH-2 top-line results. A study in those with concurrent and type 2 diabetes. 📊 Mean body weight change at 80 weeks: ⬇️ Original Article: Triple–Hormone-Receptor Agonist Retatrutide

This price tag often forces patients to choose between their health goals and their financial stability, a decision nobody should have to make

Suppressed macrophage infiltration followed by reduced macrophage foam cell formation by active forms of GLP-1 and GIP was demonstrated by Nagashima M, et al

However, as with injectable GLP-1s, cost may be a consideration in determining access to the Wegovy pill, particularly since many insurance plans dont cover obesity medications, Dushay says

GLP-1 drugs like semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda) do not appear on standard blood tests, drug screenings, or employment panels